Q-omics provides the consensus-scored CBLN1 profile across patient tissues and cancer cell-line models. CBLN1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CBLN1 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, CBLN1 RNA expression shows 13,640 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, LIHC, and GBM as cancer lineages where CBLN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBLN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBLN1 survival associations across molecular data types. CBLN1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBLN1 RNA expression–survival associations across cancer types. High CBLN1 expression shows unfavorable associations in KIRP, but favorable associations in LGG, LIHC, CESC, THYM and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CBLN1 RNA expression.
This table summarizes CBLN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CBLN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBLN1 shows lower tumor expression in BRCA, BLCA and HNSC and higher tumor expression in LIHC, KIRC and THCA. The LIHC box plot shows higher CBLN1 RNA expression in tumor versus normal tissue (log2 FC = +1.295, t-test p < 0.001).
This table shows molecular features associated with CBLN1 in patient tissues and cancer cell lines. In patient samples, CBLN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CBLN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_SCLC.
